|
AKR1C3-activated Prodrug AST-3424 Clinical Trials
1 actively recruiting trial across 1 location
Also known as: AKR1C3-activated Prodrug OBI-3424, AKR1C3-activated Prodrug TH-3424, AST-3424, Aldo-keto Reductase 1c3-activated Prodrug OBI-3424, OBI 3424, OBI-3424, OBI3424, TH 3424, TH-3424, TH3424
Birmingham, Alabama1 trial
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
University of Alabama at Birmingham Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.